Updates from the American Society of Hematology (ASH) Annual Meeting Webinar 2019

Description: HOPA is pleased to present the first of a five-webinar series, which will review key findings from clinical and translational research, and data presented at national oncology meetings. This program summarizes key abstracts presented at the 60th Annual Meeting of the American Society of Hematology (ASH). Information highlighted includes recent advances in hematologic malignancies, hematopoietic cell transplantation, and chimeric antigen receptor T cell therapy. By watching this presentation, the audience will gain insight into potential practice-changing outcomes that will surely influence the standard of care in these areas.

Learning Objectives

  • Describe the pertinent research in malignant hematology and hematopoietic cell transplantation (HCT) presented at the 2018 American Society of Hematology (ASH) Meeting
  • Interpret results and conclusions from key abstracts presented at the ASH 60th Annual Meeting
  • Identify significant advances in malignant hematology and HCT anticipated to impact clinical practice


Elizabeth DiMaggio

Elizabeth DiMaggio, PharmD BCOP

Dr. Elizabeth DiMaggio received her Doctor of Pharmacy degree from Palm Beach Atlantic University in 2010. After her first-year pharmacy practice residency, she completed a specialized PGY2 residency in Oncology at UF Health Shands Hospital in Gainesville, Florida. Following post-doctoral training, Dr. DiMaggio was the Hematology/Oncology Clinical Specialist at Dartmouth Hitchcock Medical Center in New Hampshire until she transferred down to the Moffitt Cancer Center 2014. She is board certified in Oncology Pharmacy and currently practices as a Clinical Pharmacist in Blood and Marrow Transplantation at Moffitt Cancer Center in Tampa, Florida.

Disclosure: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-054-H04-P.

Activity Type:


Accreditation Statement:

logo acpeThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 6, 2022.

education speaker bpslogoThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% or greater is achieved. Tests must be completed by September 3, 2019.

Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.

Individual webinar pricing:
HOPA Member Price: $40 / Non-Member Price: $70

Purchase now